Home » NOVARTIS ACQUIRES MARKETING RIGHTS OF NEW VACCINE
NOVARTIS ACQUIRES MARKETING RIGHTS OF NEW VACCINE
Swiss pharmaceutical giant Novartis AG Tuesday announced that it was acquiring the marketing and distribution rights for IC51, a new vaccine in phase three trials, from Austria's Intercell AG. As per the terms of the deal, Novartis will make an equity investment worth €30 million in the Austrian company.
Newratings (http://www.newratings.com/analyst_news/article_1296099.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May